StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $0.27 | $0.25 | -9.53% | 1.1M |
| 05-13 | $0.26 | $0.31 | +21.71% | 3.8M |
| 05-14 | $0.32 | $0.31 | -4.77% | 1.1M |
| 05-15 | $0.29 | $0.29 | -0.58% | 0.4M |
| 05-18 | $0.28 | $0.27 | -6.18% | 0.3M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for NOTV.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for NOTV.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Annual 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $238.53M | $120.88M | $513.02M | $374.88M |
Operating Income | $-35.64M | $-16.33M | $-30.90M | $-24.12M |
Net Income | $-60.84M | $-28.38M | $-68.63M | $-60.07M |
EPS (Diluted) | $-1.76 | $-0.83 | $-2.11 | $-1.89 |
Total Assets | $702.42M | $734.34M | $771.11M | $759.74M |
Total Liabilities | $625.32M | $625.31M | $635.09M | $615.95M |
Cash & Equivalents | $15.18M | $12.73M | $21.74M | $6.21M |
Free Cash Flow OCF − CapEx | $-13.79M | $-10.61M | $-27.07M | $-38.70M |
Shares Outstanding | 34.89M | 34.39M | 34.36M | 34.35M |